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CHAPTER 2 The lmmune System 
Betty Bierut Gallucci, PHD 
Donna McCarthy, PHD 
Modern biotherapy has been in use for sorne 
30 years. The first types of biotherapy were 
nonspecific stimulators of the immune re-
sponse, but advances in genetic engineering 
are allowing the mass production of pure bio-
logical products which are now being tested 
as pharmaceutical agents. Biotherapy con-
notes the administration of products (1) that 
are coded by the mammalian genome; (2) that 
modify the expression of mammalian genes; 
or (3) that stimulate the immune system. In 
this chapter the discussion of the immune sys-
tem will be limited primarily to topics relevant 
to cancer or autoimmune diseases. 
Because understanding the new biological 
agents requires an understanding of both the 
immune response and the molecular basis of 
oncogenesis, this chapter first presents a sum-
mary of the structure and function of the im-
mune system. Following a discussion of im-
mune responses, and the cells involved in 
these responses, will be a discussion on the 
current concepts of oncogenesis, particularly 
oncogenes and growth factors. Because re-
search efforts are beginning to identify many 
biological proteins as having a role in autoim-
mune and other diseases, a brief introduction 
to autoimmune diseases is also included at the 
end of the chapter. 
THE IMMUNE SYSTEM 
Overview of 
the lmmune Response 
The immune system is a complex, dynamic 
system which evolved to protect the individ-
ual against pathogenic organisms (Figure 2.1). 
In addition to recognizing and destroying for-
eign substances or antigens, immune re-
sponses can also destroy altered and malig-
nant cells. This latter function of the immune 
system is called immune surveillance. The 
destruction of microorganisms and the de-
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Figure 2.1 The humoral branch and cell-mediated branches of the immune system. The humoral 
response involves interaction of B lymphocytes with antigen and their differentiation into antibody-
secreting plasma cells. The secreted antibody binds to the antigen and facilitates its clearance from 
the body. The cell-mediated response involves various subpopulations of T lymphocytes that 
recognize antigen p,resented on self-cells. T H-cells respond to antigen with the production of 
lymphokines and cytotoxic T lymphocytes (CTL) mediate killing of cells that have been altered by 
antigen (e.g., virus-infected cells). 
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Table 2.1 
Protection 
Surveillance 
Homeostasis 
Tolerance 
Regulation 
Functions of the lmmune System 
Recognition and destruction of 
pathogenic microorganisms 
Destructio.p of malignant cells 
Destruction of worn and damaged 
ce lis 
Recognition of self components 
Augmentation and depression of 
immune responses 
struction of tumor cells involve the same im-
munologic mechanisms. The mechanisms 
used to fight viral diseases are particularly 
important in immune responses to tumors. 
See Table 2.1 for a summary of functions of 
the immune system. 
lmmune responses involve a number of 
different cell types and their products. Be-
cause it is impossible to discuss or study all 
the responses at the same time, they are di-
vided into two types, innate and adaptive. 
Innate immunity is also called natural or non-
specific immunity and includes the inflamma-
tory response. Adaptive immunity is also 
k.nown as specific or acquired immunity. For a 
review of innate and adaptive immune re-
sponses, see Table 2.2. 
Innate immunity is the first line of defense 
against pathogenic organisms; adaptive im-
munity involves the recognition of specific 
foreign determinants and a memory response. 
To recognize and destroy what is foreign also 
implies that the immune system must be able 
to tolerate self, that is, to tolerate its own cells 
and their products. If the molecules on the 
microorganism or tumor cell are recognized 
as foreign (nonself or altered self) and stimu-
late a specific immune response, they are 
called antigens. The small area of the antigen 
that binds to the lymphocyte receptor is the 
antigenic determinant or epitope. 
The cells and products of innate and 
adaptive immune responses act in concert and 
are aH responsible for resistance to pathogens 
and surveillance. For instance, the first line of 
defense against pathogenic organisms (e.g. 
Pseudomonas) are mechanical barriers such as 
intact skin and mucous membranes. If these 
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physicaJ barriers are breached, an inflamma-
tory response attempts to limit the coloniza-
tion of the microbe. The acute inflammatory 
response involves the physiological processes 
of capillary dilatation, exudation of fluid and 
plasma protein into the tissues, and accumula-
tion of neutrophils at the site of infection. 
These responses are manifested clinica11y as 
the five cardinal signs of inflammation: heat, 
redness, swelling, pain, and loss of function. 
The invading organism is then killed through 
phagocytosis by neutrophils or soluble chemi-
cal factors generated during the inflammatory 
response (Figure 2.2). The influx of neu-
trophils is replaced by monocytes, which con-
tinue to migrate to the inflammed area. The 
activation of monocytes is the bridge between 
innate and adaptive immunity. Monocytes are 
capable of processing the antigen they pha-
gocytize and presenting it to other white 
blood cells involved in adaptive or specific 
immunity. 
Thus, if this innate response fails and the 
organism colonizes the body, the adaptive im-
mune system is stimulated and responds. The 
specific immune response on the next expo-
sure to the same antigen will be heightened 
and more rapid. This secondary response is 
called memory or anamnestic response. 
Generally speaking, the white blood cells 
are responsible for immune responses; granu-
locytes (neutrophils, eosinophils, and baso-
phils), monocytes and their tissue counterparts 
macrophages are involved in innate immunity, 
whereas lymphocytes are responsible for spe-
cific immun~ responses. Lymphocytes have 
two different ways of recognizing antigenic 
determinants. The first is by antibodies located 
on the membrane of B lymphocytes and the 
second is by T-lymphocyte (or T-cell) recep-
tors. For the T-cell receptors to recognize the 
antigenic determinants the antigen must be 
present along with self molecules or major his-
tocompatibility (MHC) molecules. Typically, 
both the innate and adaptive systems (both B 
and T lymphocytes) are needed to effect a 
response sufficient to contain and eliminate 
pathogens. 
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Table 2.2 Features of innate and adaptive immunity 
System 
lnnate lmmunity 
Adaptive lmmunity 
ANTIGENS 
Hallmarks 
Primary line of defense 
Non-specific 
·No memory 
Secondary line of defense 
Specificity 
Memory 
The majar function of the immune system is to 
distinguish between self molecules and non-
self or altered-self molecules. Molecules that 
induce a specific immune response are called 
immunogens. AJI immunogens are also anti-
gens. Allergens are antigens that induce aller-
gic responses. The epitope or antigenic deter-
minant is that specific part of an antigen, 
allergen, or immunogen that binds directly 
with the immunoglobulin or T-cell receptor. 
For example, an antigenic protein may consist 
of hundreds of amino acids, but only six or 
seven of these bind directly with an immu-
noglobulin. The binding area of the antigen is 
the epitope. Tolergens are molecules that in-
duce a state of immunologic unresponsive-
ness. Most times antigens are exogenous mol-
ecules such as bacteria! or viral proteins. 
Rarely, immune responses are generated to 
self molecules, that is autoantigens or auto-
logous antigens, resulting in serious patho-
logic states caBed autoimmune diseases. Al-
loantigens are endogenous molecules that 
Features and Functions 
Mechanical Barriers 
lntact Skin 
Mucous Membranes 
Chemical Barriers 
lnflammatory response 
Fever 
Phagocytic Cells 
Soluble Factors 
Protects against pathogens 
Lymphocytes 
T-cells: Provide cell mediated 
immunity 
Primarily protects against intracellular 
organisms, immune surveillance, 
responsible for rejection of transplanted 
organs and modulation of immune 
response 
B-cells: Provide humoral immunity 
Primarily protects against viruses and 
bacteria 
distinguish one individual from another indi-
vidual of the same species. The A, B, and O 
blood-type molecules and the histocompati-
bility antigens are examples of alloantigens. A 
bone marrow transplant between siblings is 
caBed an allogeneic transplant. 
The distinction between self molecules 
and foreign molecules is a learned response. 
Exposure of the immune system to molecules 
in utero will generate tolerance to these mole-
cules: the immune system will not respond to 
these molecules, rather they will be consid-
ered self molecules (self antigens). The greater 
the difference between self molecules and ex-
ogenous or foreign molecules, the more likely 
it is that an immune response will be gener-
ated. Also, the greater the evolutionary diver-
gence between two species, the greater the 
likelihood that an immune reaction will occur. 
In humans, for instance, an immune response 
to avian albumin is more likely than a re-
sponse to primate albumin. There are, how-
ever, sorne proteins that are phylogenetically 
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Figure 2.2 The inflammatory response. A bacteria! infection causes tissue damage with release of 
various vasoactive and chemotactic factors. These factors induce increased blood flow to the area, 
increased capillary permeability, and the influx of white blood cells, including phagocytes and 
lymphocytes, from the 
1
blood into the tissues. The serum proteins contained in the exudate have 
anti-bacterial properties and the phagocyte will begin to engulf the bacteria . 
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Source: IMMUNOLOGY by )anis Kuby. Copyright (e) 1992 by W.H. Freeman and Company. Reprinted with permission . 
conserved, such as collagen; these proteins 
will not generate immune responses even if 
transplanted across species lines. 
Besides the degree of foreignness, the size 
and the chemical nature of the molecules will 
determine if a specific immune response is 
generated. In general, proteins are more effi-
cient immunogens than other compounds; 
complex carbohydrates are also good immu-
nogens. Lipids and nucleic acids are poor im-
munogens unless they are bound to proteins. 
A complex molecule is likely to generate an 
immune response, whereas polymers com-
posed of a single amino acid are unlikely to 
generate a response. The B and T lymphocytes 
will recognize different epitopes on the same 
molecule. For the T cell to recognize a mole-
cule as foreign, the molecule first must be 
phagocytized and processed, and then small 
segments of the molecule must be linked to 
MHC molecules on the surface of the acces-
sory cell. Molecules that resist digestion by 
phagocytes are less likely to stimulate a 
T-helper cell response. If the T-helper re-
sponse is limited, then neither a B-cell re-
sponse nor a T-cell response is likely. The 
route by which the antigen is presented to the 
immune system and the dosage will affect the 
type and degree of immune responses. Anti-
gens present in the mucosa are much more 
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likely to generate immunoglobulin A or E 
than immunoglobulin G. A systemically ad-
ministered antigen is likely to produce an im-
munoglobulin G response. If the antigen is 
administered in yery high quantities or in 
very low quantities, the host may come to 
tolerate the antigen. 
Mitogens are molecules that can induce 
nonspecific division and activation of lympho-
cytes; mitogens will also stimulate many 
clones of lymphocytes. This contrasts with the 
specific stimulation of a single lymphocyte 
clone by an antigenic epitope. Mitogens are 
used in laboratory situations to test the func-
tional ability of lymphocytes. Sorne common 
mitogens used in testing of lymphocytes are 
phytohemagglutinin (PHA), concanavalin A 
(Con A), and pokeweed mitogen (PWM). Both 
PHA and Con A are proteins derived from 
plants and are T-cell mitogens; PWM stimu-
lates both T and B cells. These protein mito-
gens are also known as lectins. Sorne bacteria! 
toxins act like mitogens in that they non-
specifically stimulate multiple colonies of lym-
phocytes. Super antigens are very potent 
T-cell mitogens and stimulate T-helper cells, 
an example of a super antigen is the toxic 
shock syndrome toxin. This stimulation may 
lead to a massive release of cytokines and to 
shock and death. The lipopolysaccharide in 
bacteria! endotoxin is another example of a 
super antigen. 
CYTOKINES 
Cytokines and lymphokines are discussed 
here because these molecules are a part of a 
network of mediators released in inflamma-
tory and specific immune responses. These 
compounds are produced primarily by T cells, 
but they can be produced by other types of 
cells such as monocytes, or their mature coun-
terpart, macrophages. The term et;tokine de-
scribes a soluble protein produced by cells, 
and includes polypeptide molecules such as 
interleukins, lymphokines, monokines, inter-
ferons, tumor necrosis factor, and transform-
ing growth factor. They are biologically very 
active, have short half lives, and are functional 
at low concentrations. Cytokines bind to 
plasma membrane receptors; they affect the 
growth and differentiation of white blood 
cells, and regulate immune and inflammatory 
responses. 
Cytokines act as signals between cells and 
can exert their effect in the same cell from 
which they were secreted, that is, in an auto-
crine action. Cytokines can affect cells in the 
immediate area, a paracrine action, or they 
can exhibit endocrine actions, that is, on dis-
tant cells. A cytokine can have different effects 
in different target cells, that is, they are 
pleiotropic. Cytokines can also act in concert: 
one cytokine may potentiate (or inhibit) the 
action of another cytokine. This effect is 
known as the cytokine cascade. 
When a T-helper cell is activated by an 
antigen, for instance, the cell can secrete a 
variety of cytokines, which in turn actívate B 
cells, NK cells, other T cells, macrophages, or 
stem cells. The target cells secrete the same 
cytokine or another cytokine which can either 
amplify or inhibit the immune response. Often 
more than one cytokine is needed for cellular 
activation, and the sequence of exposure to 
the cytokines may also be important. lt is best 
to consider cytokines as a system or a network 
in which the cytokines can act in a redundant, 
synergistic, antagonistic or pleiotropic fash-
ion. (See Figure 2.3.) 
When cytokines were first studied, their 
chemical structures were not known, so func-
tional assays were developed for each one. 
Each cytokine was studied and named by the 
action it produced. For instance, investigators 
who studied a substance that destroyed 
tumor cells named it tumor necrosis factor 
(or lymphotoxin). Other investigators who 
studied a substance that caused weight loss 
called it cachectin. When the chemical na-
tures of these compounds were described, it 
was discovered that tumor necrosis factor, 
lymphotoxin, and cachectin were really the 
same compound. More than one name exists 
for many of the cytokines. In 1986 an intema-
lional system was established to try to stan-
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Figure 2.3 Examples of the cytokine attributes of pleiotropy, redundancy, synergism, and 
antagonism. 
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Source: IMMUNOLOCY by janis Kuby. Copyright (e) 1992 by W.H . Freeman and Company. Reprinted with permission. 
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dardize the cytokine nornenclature. (See 
Chapter 5.) When the DNA sequence coding 
for a protein has been discovered, it is now 
given an interleukin designation. The terrn in-
terleukin Jiterally rneans "between white 
cells," however, sorne of these protein mole-
cules are rnade by, or act on, cells other than 
white blood cells. 
An example is interleukin-6 (See chapter 
16). Previously it was called B-cell differentia-
tion factor, B-cell stirnulation factor, hepato-
cyte-stimulating factor and interferon-¡32, de-
pending on the assay used. Interleukin-6 
stimulates T-cell proliferation and differentia-
tion in addition to the production of IL-2 and 
IL-2 receptors by the T-cell. Interleukin-6 also 
stirnulates plasma cells to secrete immunoglo-
bulins and hepatocytes to secrete acute phase 
response proteins such as C reactive protein. 
Interleukin-6 is also important in hernato-
poiesis. It is produced not only by T-helper 
cells but also by rnacrophages and fibroblasts. 
Therefore, it acts in a pleiotropic, redundant, 
and synergistic fashion. Since it can also be 
manufactured by and influence cells other 
than white blood cells, the term cytokine rnay 
be better than interleukin. 
Cytokines rnay also play a role in bidirec-
tional cornrnunication between the neuroendo-
crine and irnrnune systems. For example, inter-
feron-c:x can increase the levels of circulating 
cortisol. Interleukin-2 infused in pharmacologic 
doses can cause fatigue and depression. Sorne 
of the cytokines induce fever by affecting the 
temperature-regulating center in the hypothala-
mus. Thus, cytokines rnay be important for in te-
grating the irnmune response within the total 
person, not just within the immune systern. 
Likewise, changes in the neuroendocrine sys-
tern can heighten or diminish irnmune re-
sponses. Hormones such as cortisol and the sex 
hormones generally depress the immune re-
sponses, whereas growth hormone and thy-
mosin enhance T -cell responses. This comrnuni-
cation between systems is possible because 
there are receptors on the surfaces of lympho-
cytes and other white blood cells for hormones 
such as cortisol and epinephrine, while the ner-
vous systern has receptors for cytokines such as 
interferon-c:x and IL-2. 
MAJOR HISTOCOMPATIBILITY 
COMPLEX 
Regulation of irnmune responses occurs at 
many levels: by antigens, cytokines (between 
cells), and the neuroendocrine system. The 
ability to respond toan antigen is determined 
not only by the factors listed above but also by 
the genetic constitution of the individual. The 
part of the genome that we know the rnost 
about with respect to immune responses is 
called the major histocompatibility complex 
(MHC). This area was first studied in relation-
ship to transplantation of tissue. Because the 
first cells used for testing the compatibility of 
tissues between individuals were lyrnpho-
cytes, in hurnans the MHC is called the hu-
man leukocyte antigen (HLA) complex. Here 
the term antigen is used, because lyrnphocytes 
from one person or donar, would be foreign to 
another person, or recipient, and would stim-
ulate an immune response to the donar cells 
in the recipient. Much of the research done in 
this area has used rodent models. In the 
rnouse, the MHC is called the H2 complex (H 
for histocornpatibility and 2 for the second 
erythrocyte antigen of the mouse). 
The MHC or HLA genes are located on 
chromosorne 6 and code for molecules on the 
cell membrane needed for the presentation of 
the antigen to T lyrnphocytes. These genes 
also code for sorne soluble molecules, includ-
ing those of the cornplement systern and 
tumor necrosis factor. The MHC cornprises 
about 40 to 50 genes and, although the func-
tions of many are understood, others are not. 
The HLA is further divided into class I, ll, and 
III regions; the genes code for class I, II, and Ili 
molecules. These MHC molecules are often 
referred to as MHC antigens. 
Class I genes are located at the HLA-A, 
HLA-B, HLA-C, -E, -F and -G loci. The locus is 
the position on the chromosorne where a gene 
is positioned. The HLA genes are located on 
the short arm of chromosome 6. The class I 
-genes code for molecules that are present on 
most nucleated cells. For a cytotoxic T cell to 
recognize an antigen, the antigen must be 
complexed with a MHC class I molecule. Con-
sidering that a virus can infect any cell in the 
body and that the cytotoxic T cell is responsi-
ble for killing cells infected with viruses, it 
makes sense that class I molecules are ubiqui-
tous. Class I molecules are absent in sperm 
and in trophoblasts. Sorne cells of the body, 
such as liver cells, fibroblasts, and neurons, 
express very Iow Ievels of these genes. Per-
haps the reason for the success of liver trans-
plantation and the acceptance of the fetal tis-
sues as grafts is the Iow numbers of class I 
molecules on the membranes of these cells. 
Cytokines such as tumor necrosis factor and 
interferons can increase (up-regulate) the ex-
pression of these genes, increasing the num-
bers of class I molecules on the surfaces of 
these cells. 
Class li molecules are found on ce lis of the 
immune system: B lymphocytes, antigen-pre-
senting cells, accessory cells, macrophages, 
Langerhans cells, and dendritic cells. The ma-
jor role of class II molecules involves the pre-
sentation of the antigen to T-helper cells. The 
antigen is first processed, then it binds to the 
class II molecule; it is this complex that binds 
to and stimulates the T-helper cell. The class II 
genes are Iocated at the DO, DP, DQ, DR, DV, 
DX, and DZ Ioci. The class II genes are also 
known as the immune response genes and 
determine the leve! of response to an antigen. 
Certain animal strains that tend to respond 
quantitatively more to an antigen than other 
strains are called high responders. The exis-
tence of high and Iow responder strains is due 
to differences in the MHC class II genes. Be-
cause both class I and II molecules have sorne 
structural similarity to the immunoglobulin 
molecules, they are considered to belong to 
the immunoglobulin superfamily. 
Class III genes code for sorne of the pro-
teins involved in the complement pathway, 
tumor necrosis factor, and steroid hydrox-
ylase enzymes. These molecules are soluble, 
diverse, and have no role in presentation of 
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the antigen. The class III genes lie between the 
class II and class I genes on the chromosome. 
Haplotypes 
There are many variants or alleles of each of 
the MHC genes, allowing many variants in 
each of the class I and class li molecules. This 
Ieads to the great diversity seen in humans 
and accounts for the difficulties in transplan-
tation among unrelated donors. The MHC 
genes are tightly linked. Usually, one copy of 
the entire MHC gene (a haplotype) is inher-
ited as a unit from the mother and another 
copy is inherited from the father. Twenty-
three different alleles are known for the HLA-
A Iocus of MHC class I, 49 for the HLA-B 
Iocus, and eight for the HLA-C Iocus. If there 
are 50 genes in the MHC and there are many 
variants of these genes; it is easy to see why it 
is difficult to match for histocompatibility. 
Theoretically, the number of possible MHC 
genotypes in the human population would be 
the number of alleles for each gene multiplied 
by every other possibility, i.e. 23(A) x 49(B) x 
8(C) and so on for the 50 genes. In actuality, 
the total number of possibilities is Iess than 
the theory predicts because certain of these 
genes are tightly linked to each other making 
their recombination with other genes highly 
unlikely. Certain haplotypes are found more 
frequently than would be expected, so that in 
isolated populations a greater frequency of 
certain alleles of the MHC wiii be found. Be-
cause of the. tight linkage, there is one chance 
in four that siblings will share the same hap-
Iotypes. In an individual cell both the mater-
nal and paternal genes are expressed, that is, 
the genes are codominant. 
TISSUES ANO CELLS OF THE 
IMMUNE SYSTEM 
The Lymphoid System 
The cells responsible for the immune response 
are organized into tissues and organs collec-
tively known as the Iymphoid system. Lym-
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phoid tissue can be designated as primary or 
secondary. The primary organs include the 
bone marrow and the thymus, and are the 
sites where lymphpcytes develop and mature. 
Secondary lymphoid organs include the 
lymph nades, lymph vessels, spleen, tonsils, 
and unencapsulated lymphoid tissue lining 
the respiratory, alimentary and genito-urinary 
tract. Lymphocytes are stored and activated in 
the secondary organs. Lymph nades are 
chains of encapsulated lymphoid tissue hous-
ing B- and T-lymphocytes. They are found 
throughout the body and are located primar-
ily at the junctions of lymphatic vessels, a 
network that drains and filters tissue fluid . In 
sum, lymph nades filter material draining 
from body tissues, the spleen fil ters antigens 
in the blood, and the unencapsulated lymph 
tissue monitor mucosa! surfaces. 
Cells of the lmmune System 
The white blood cells (granulocytes, mono-
cytes, lymphocytes) responsible for immune 
responses are derived from bone marrow 
stem cells in children and adults and the yolk 
sack, spleen, and liver in the fetus. The stem 
cells are pluripotent, that is, capable of pro-
ducing all the formed elements of the blood, 
including erythrocytes (red blood cells) and 
platelets. This process of differentiation or 
maturation is called hematopoiesis. Nu-
merous growth and differentiation factors that 
support hematopoiesis have been identified. 
(See chapter 6.) 
Many of the hematopoietic growth factors 
were identified by culturing bone marrow 
stem cells in vitro. Since each cluster of cells 
that grew in culture was derived from a single 
cell, these growth factors were called colony-
stimulating factors. There are four main types 
of colony-stimulating tactors: multil ineage 
colony-stimulating factor, also called interleu-
kin-3 (IL-3), granulocyte-macrophage colony-
stimulating factor (GM-CSF), granulocyte col-
ony-stimulating factor (G-CSF), and macro-
phage colony-stimulating factor (M-CSF). 
Other cytokines secreted by T-helper lympho-
cytes and macrophages that support hema-
topoiesis include such factors as interleukins-
1, -4, - 5, -7, -8, and -9 (IL-1, IL-4, IL- 5, IL-7, 
IL-8 and IL-9). Different growth factors are 
necessary at different stages of maturation. 
Multilineage colony-stimulating factor is im-
portant early in the differentiation of the my-
eloid line of blood cells (erythrocytes, mono-
cytes, and granulocytes), whereas G-CSF is 
important in a later stage of differentiation of 
the neutrophil line. (See Figure 2.4.) 
Granulocytes 
Neutrophils, or polymorphonuclear leuko-
cytes, are important early in the inflammatory 
process and in acute infections. They are the 
most numerous of all the leukocytes, account-
ing for approximately 50% to 70% of circulat-
ing white blood cells. Neutrophils migrate 
from the blood stream into the tissue, where 
they phagocytize pathogens and cellular de-
bris. The ability of these cells to recognize 
what is antigen (and should be destroyed) is 
poorly understood but is thought to involve 
the chemical structure of the antigen. For ex-
ample, the cell wall of sorne bacteria contain 
complex polysaccharides that are not seen in 
the cell wall of humans. Antibodies, produced 
by B lymphocytes, may bind to the antigen 
and mark it for destruction by neutrophils or 
monocytes. Other circulating proteins known 
as opsonins may bind to the antigen, also 
marking it for phagocytosis by neutrophils or 
monocytes. Basophils contain granules, and 
have mediators such as histamine, which are 
important in allergic reactions. In tissues, cells 
similar to basophils are called mast cells. Eo-
sinophils are phagocytes and play a role in 
immune responses to parasitic worms. They 
are present in small numbers in blood: they 
constitute about 1% to 3% of circulating white 
blood cells. 
Monocytes and the Mononuclear 
Phagocyte System 
Monocytes are large phagocytic cells that 
comprise approximately 3% to 7% of the circu-
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Figure 2.4 Cells of the immune system. 
Overview of the lmmune System 
• 
Neutrophil Basophil Eosinophil 
White blood cells (WBC) 
(leukocytes) 
Polymorphonuclear (PMN) leukocytes 
(also known as granulocytes) /Cf), 
~~~· N~La ~clu• 
8 lymphocyte T lymphocyte lymphocyte phagocyte 
~--------------~-------------------__J 
lating white blood cells. They are present late 
in the inflammatory process and in chronic 
infections. Tissue monocytes (also called mac-
rophages), when present along with lympho-
cytes, are often designated as a monocytic in-
filtrate on histologic examination. Macro-
phages contain many granules and lysosomes 
and are very effective in removing cellular 
debris, which is why they are often called the 
"mop up troops." Many tissues contain resi-
dent macrophages, which are called different 
names in different tissues. For instance, mac-
rophages in the liver are called Kupffer cells; 
in the skin, Langerhans cells; and in the brain, 
glial cells. This system of macrophages has 
Mononuclear leukocytes (MNL) 
been renamed the mononuclear phagocytk 
system; it was previously termed the reti-
culoendothelial system. 
Macrophages are not only important in 
innate responses, but also they play a vital 
role in adaptive immune responses. Macro-
phages are often involved in the first stage of 
processing antigens and presenting them to 
lymphocyte populations. Foreign microorga-
nisms are phagocytized by the macrophage 
and then digested in the phagosomes. Parts of 
the digested foreign molecule are further pro-
cessed inside the cytoplasm; these eventually 
bind to the macrophage cell-surface proteins 
and are expressed on the cell surface. The 
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antigen, in combination with these cell-surface 
proteins or class II MHC markers, are pre-
sented to the lymphocyte. The lymphocyte 
specific for that antigen then binds to the anti-
genic determinant" and is activated. The cells 
responsible for processing antigens are also 
known as antigen processing cells or acces-
sory cells. Macrophages can also bind anti-
bodies on their cell surfaces, which will permit 
them to more readily phagocytize specific an-
tigens. When the antigen and antibody bind, 
the macrophage is thus activated and becomes 
more efficient in destroying invading micro-
organisms. 
Lymphocytes 
Lymphocytes constitute about 20% to 40% of 
circulating white blood cells and are responsi-
ble for the recognition of antigens and induc-
tion of adaptive (specific) immune responses. 
Lymphocytes also reside in lymphatic tissues 
throughout the body, which include such 
structures as the tonsils, adenoids, lymph 
nades, thymus, spleen, appendix, Peyer's 
patches, and bone marrow. The lymphatic tis-
sue underlining the mucous membranes, 
MALT (mucosa-associated lymphatic tissue), 
BALT (bronchus-associated lymphatic tissue), 
and GALT (gut-associated lymphatic tissue), 
is not encapsulated, nor is itas well organized 
as that of the lymph nades. In the mucosa, 
these loase dusters of lymphocytes can inter-
act with antigens at the lumenal surface and 
prevent antigens from gaining access to the 
systemic circulation. 
Lymphocytes recirculate throughout the 
body by leaving the vasculature or lymphatic 
tissue and infiltrating tissues. They then re-
enter the circulation via lymphatic vessels and 
once again take up residence in the lymphatic 
tissue. Lymphocytes possess adhesion and 
homing receptors on their surfaces, which 
permit them to bind to the vascular endo-
thelial cells in general and endothelial cells in 
specific tissues. The venule endothelial cells 
possess vascular adhesion molecules which in 
turn bind with the lymphocyte homing recep-
tors. This recirculation of lymphocytes en-
sures that antigens come in contact with re-
sponsive lymphocytes. lt is thought that only 
1 in 1,000 to 1 in 100,000 lymphocytes have the 
ability to respond to a specific antigen. 
Although al! lymphocytes look similar in 
a routine blood smear, there are subpopula-
tions. The current method to distinguish cell 
populations and subpopulations is by staining 
cell surface molecules with monoclonal anti-
bodies linked to fluorescent dyes. Monoclonal 
antibodies are highly specific antibodies pro-
duced from a single clone of cells. (See Chap-
ter 7.) These surface molecules are called clus-
ter of differentiation (CD) antigens (or CD 
markers). The monoclonal antibodies that are 
attached to the cell markers and the markers 
themselves have been assigned CD numbers 
by an international workshop. Of the three 
majar populations of lymphocytes, T lympho-
cytes, B lymphocytes, and natural killer (NK) 
cells, T and B lymphocytes are responsible for 
specific immune responses and natural killer 
cells are involved in innate immune reactions 
to viruses and tumors cells. Although CDS is 
a marker for both T and B cells, COl, CD3, 
and CD7 are markers only for T cells; CD21, 
CD22, CD37, and CD40 are a few of the 
antigens associated with B cells. CD56 is a 
marker for NK cells. In many cases the func-
tion of the cell surface molecule is known. 
For instance CD21 on B cells is a receptor for 
a complement molecule and is also the Ep-
stein-Barr virus receptor. 
8 Lymphocytes In humans, the stem cells for 
B lymphocytes are located in the bone mar-
row. In the bird, however, B cells mature in a 
Iymphoid organ called the bursa of Fabricius, 
which is similar in structure to the human 
appendix. Since it was in the bird that the 
function of B cells was first determined, now 
al! lymphocytes that secrete antibodies are 
called B cells. The molecules on the surface of 
B cells that are responsible for binding antigen 
are called membrane-bound immunoglobu-
lins (lg) . On the surface of any one B cell, all 
the immunoglobulin receptors are identical in 
structure and thus bind to only one particular 
antigen. The most mature form of the B lym-
phocyte is the plasma' cell, whose function is 
to secrete immunoglobulins (i.e., antibodies). 
All the daughter cells derived from a single B 
cell will produce the same antibody, therefore 
the name monoclonal antibody is given to the 
immunoglobulin secreted from a particular 
clone of B cells. Antibodies or immunoglo-
bulins are found in the plasma, the fluid por-
tian of blood; therefore the historical name 
associated with the specific immunity pro-
duced by B cells is humoral immunity. Other 
names associated with B cell immunity are 
antibody-mediated immunity and immediate 
hypersensitivity reactions. (See Figure 2.5). 
The B lymphocytes constitute approx-
imately S% to 15% of circulating lymphocytes; 
plasma cells, however, do not circulate but 
remain fixed in the lymphoid tissue. Collec-
tions of B cells in lymphoid tissue stain in-
tensely. These collections of B cells are called 
primary and secondary follicles (or germinal 
centers). Because B cells predominate, the col-
lections are also called T-independent areas in 
the lymph nades. Small amounts of T cells and 
macrophages are present even in the T-inde-
pendent areas. Many B cells require the pres-
ence of T cells and accessory cells to manufac-
ture antibodies. 
T Lymphocytes T lymphocytes are derived 
from a population of lymphocytes that mature 
in the thymus. Lymphocyte stem cells migrate 
from the bone marrow to the thymus in the 
fetus and in childhood. In the thymus, lym-
phocyte populations that will react to self mol-
ecules (or self antigens) are eliminated and the 
other T cells differentiate. As the T cells ma-
ture, they leave the thymus and migrate to the 
lymphatic tissue, populating the areas sur-
rounding the germinal centers, paracortical 
areas. The T lymphocytes constitute about 
70% to 80% of circulating lymphocytes. They 
are responsible for immune reactions such as 
graft rejection, graft-versus-host disease, con-
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tact skin sensitivity, and delayed hypersen-
sitivity reactions. 
Much of what we know about the T cells 
was discovered in the nude (hairless) mouse. 
Because these mice are born without a thy-
mus, they are unable to reject transplanted 
tissue even if the tissue is from another spe-
cies. Nude mice are often used as incubators 
of human tumor cell lines because they are 
unable to reject the foreign tissue. The T lym-
phocytes are also important regulators of im-
mune responses. As with all physiological re-
sponses, regulation of the immune response is 
necessary to either stimulate or inhibit the re-
actions. 
Like B cells, T cells can recognize and bind 
to specific antigens. lt is the T-cell receptor 
that binds the antigen. There are two types of 
T-cell receptors, TCRl and TCR2; anda partic-
ular T cell possesses only one of these types. 
In the T-cell membrane, the T-cell receptor is 
linked to a molecule called CD3. The T cell can 
recognize a foreign antigen only if it is linked 
to a self molecule (also known as MHC anti-
gens) on the surface of another cell. The T-cell 
immune responses are particularly effective in 
eliminating intracellular pathogens, for in-
stance, cells that are infected with a virus and 
express viral antigens on their cell surfaces. 
This is in contrast to the immunoglobulins, 
which can bind to soluble antigens and help 
eliminate extracellular microorganisms. 
The T-lymphocyte population can be fur-
ther divided into severa! subpopulations that 
can be distinguished by the CD4 and CD8 
markers. The T4 cells (which express CD4 
markers) are called helper/inducer T-cells. 
For the T-helper cells to recognize an antigen, 
the antigen must be present on another cell 
that has MHC class H molecules. Thus, 
T-helper lymphocytes are called class 11-
restricted cells. These cells secrete cytokines 
called lymphokines, sorne of which stimulate 
the growth and differentiation of B lympho-
cytes and others of which activate macro-
phages. The T-helper lymphocytes also induce 
the generation of cytotoxic T lymphocytes. lt 
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Figure 2.5 Differentiation and maturation of T lymphocytes and B lymphocytes. T cells develop in 
the thymus from cells that originate in the bone marrow. Mature T cells interact with antigen in 
peripheral tissues and then divide and differentiate into effector T cells. B cells develop in the bone 
marrow in humans. and when mature migra te to peripheral tissues. When stimulated with antigen, 
they differentiate into antibody-secreting plasma cells and memory cells. 
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should be noted that the human immunodefi-
ciency virus (HIV) appears to bind to the CD4 
molecule on T-helper lymphocytes. The selec-
tive infection, and ultrmate de mise of T -helper 
lymphocytes, explains the amazing severity 
with which the HIV virus disables the im-
mune system. 
The cytotoxic T cells, on the other hand, 
express CDB markers and can recognize only 
antigens associated with MHC class 1 mole-
cules, that is, they are MHC class 1-restricted. 
Cytotoxic T cells can recognize and bind to 
cells with altered self antigens or viral anti-
gens bound to MHC class 1 molecules. They 
release a variety of mediators that cause the 
altered cell to lyse, or kili, the target cell. The 
suppressor T -cells al so ha ve the CDB markers 
on their surfaces. They inhibit, or down-
regulate, both T and B cell immune reactions 
and are responsible for tolerance to self. Var-
ious monoclonal antibodies are now being de-
veloped that would distinguish the cytotoxic 
T from the T-suppressor subsets and the 
helper-inducer from the suppressor-inducer 
subsets. Both helper and suppressor T lym-
phocytes are necessary for maintaining an ap-
propriate leve! of immune responsiveness. 
(See Figure 2.5.) 
Other Lymphocytes Other lymphocytes that 
are neither B or T lymphocytes include null, natu-
ral killer, killer, lymphokine activated killer 
(LAK), and tumor infiltrating lymphocytes (TIL) 
cells. Null cells are lymphocytes that lack both T 
and B cell markers; whereas the NK cells and 
other killer cells carry sorne T-cell markers or 
both T -cell and macrophage markers. At one 
time it was believed that nuU, NI<, and other 
killer cells were separate and distinct lymphocyte 
lineages. We now know, however, that as lym-
phocytes differentiate or become activated, they 
lose certain markers and gain others. Thus, sorne 
subsets may be simply more mature (differenti-
ated) forms of the same line of lymphocytes. Al-
though the exact lineage has not been worked out 
for al! the subsets of lymphocytes, they can be 
distinguished from each other by their functional 
properties and cytoplasmic characteristics. 
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Natural killer cells are large lymphocytes 
that possess membrane-bound granules that 
contain hydrolytic enzymes. They constitute 
about 15% of the circulating lymphocytes. 
These large granular lymphocytes can in cul-
ture spontaneously destroy malignant cell 
lines. Functionally, NK cells can recognize and 
destroy tumor cells without having prior ex-
posure and are not MHC restricted. Natural 
killer cells can destroy tumor cells by direct 
contact and release of perforins, molecules 
that form doughnut-shaped pores in the tar-
get cell membrane. The other process by 
which killer cells destroy target cells is by 
antibody-dependent cell-mediated cytotox-
icity (ADCC). In the process, killer cells bind 
antibodies to their surfaces. When these anti-
bodies bind to the tumor cell antigens, cyto-
toxic enzymes are released, resulting in tumor 
cell destruction. In laboratory studies, NK 
cells have potent antitumor activity early in 
tumor development and prevent the metasta-
tic spread of tumors. 
Recent biotherapy clinical trials have 
identified two other subsets of lymphocytes. 
When lymphocytes are incubated with large 
concentrations of the lymphokine interleukin-
2 (IL- 2), they are able to lyse tumor cell lines 
and fresh tumor ce lis. These Iymphokine acti-
vated killer (LAK) cells are able to destroy 
tumor cells more efficiently than normal lym-
phocytes. Tumor-infiltrating Iymphocytes 
(TIL), are isolated from excised tumors. These 
lymphocytes, when grown in culture with 
lower concentrates of IL-2 than LAK cells, 
appear to be more specific for killing tumor 
cells derived from the host. Natural killer, 
LAK, and TIL cells may al! be related to each 
other and derived from the same lymphocyte 
cell line. Only future studies will determine 
this. See Table 2.3 for a summary of immune 
cell functions . 
SPECIFIC IMMUNE RESPONSES 
The type and the strength of an immune re-
sponse is dependent on the properties of the 
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Table 2.3 lmmune system cells and their functions 
lnnate lmmunity 
Neutrophils 
Basophils 
Eosinophils 
Monocytes 
Phagocytosis; present in acute infections 
Release of local mediators (histamine); allergic reactions 
Present in allergic reactions 
Phagocytosis; present in chronic infections 
Natural Killer Cells Natural immunity to viruses and tumors; expansion of T-cell responses 
Adaptive lmmunity 
Lymphocytes 
B lymphocytes 
Plasma Cells 
Memory Cell 
T lymphocytes 
T helper 
Membrane bound lg binds to antigen 
Most mature form of B cell, produces lg 
Responsible for memory effect 
Membrane bound receptors bind to antigen 
lnitiation of immune response, secretion of lymphokines, assist B cell production 
of antibody 
Kills cells by lysis T cytotoxic 
T suppressor 
T memory 
Decreases the immune response of other T- or B-cells 
Responsible for memory effect 
antigen, which lymphocyte populations are 
activated, and the genetic and hormonal 
characteristics of the individual. The way the 
antigen is recognized will determine which 
types of immune responses occur. Each indi-
vidual produces both B-cell and T-cell re-
sponses as well as the innate immune re-
sponses to an antigen. In fact, all these 
responses are interlinked; al1 are constituents 
of an integrated defense system. The re-
sponses to a microorganism colonizing the 
host can not always be predicted, however; 
even the simplest of microbes are very com-
plex and have many molecules that can acti-
vate immune cells. Nor is there any guaran-
tee that the immune responses will be bene-
ficia!. Indeed, if one type of immune response 
prevents another more effective response, 
then the effect is detrimental. 
8-Cell Responses 
Activation of 8 lymphocytes 
Resting B lymphocytes are in the G0 (resting) 
phase of the cell cycle. When a lymphocyte is 
activated, it enters the cell cycle and moves 
through the G1, S, G2 , and division phases. In 
the S phase of the cell cycle, DNA is synthe-
sized, whereas in the G (gap) phases, no DNA 
is synthesized but RNA, proteins, and other 
compounds are synthesized. Cytokines act in 
concert at each of these phases to drive the cell 
along its cycle, which ends with mitosis or cell 
division. 
The B lymphocytes have on their cell sur-
faces immunoglobulins that act as receptors 
for the antigen. The binding of the antigen is a 
random process. lf an antigen binds tightly 
(fits) with the immunoglobulin receptor, then 
the activation process starts. The B cell inter-
nalizes the antigen and presents it along with 
a dass II MHC molecule to the T ce!!. The T 
and B lymphocytes then form a tight bond 
with each other, a T-B conjugate. The acti-
vated T cell secretes cytokines such as IL-2. 
Thus, the process of B-cell activation requires 
(1) membrane changes that induce secondary 
changes within the cytoplasm and nucleus 
and (2) the presence of cytokines such as IL-1 
and IL-4, in the early and IL-2, IL-4, and IL-5 
in the later differentiation events. When a B 
lymphocyte becomes fully differentiated, the 
antibody is no longer present on the cell sur-
face acting as a receptor but is in the cyto-
plasm of a plasma cell that is producing large 
quantities of a specific antibody. (See Figure 
2.6.) The process of clonal selection of re-
sponding B cells is the basis of the memory 
response to that antigen. 
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Figure 2.6 Activation of B cells to produce antibody. Receptors on the surface of B cells bind 
matching antigen which is then engulfed and processed by the B cell. A piece of the antigen, 
bound to a class 11 protein, is then presented on the surface of the B cell. This complex binds to a 
mature helper T cell, which releases interleukins that transform B cells into antibody-secreting 
plasma cells. When released into the bloodstream, antibodies lock onto matching antigens and are 
eliminated by the complement cascade or by the liver and the spleen. 
8 cell QAntigen Antibodies are triggered when a 8 cell encounters its matching antigen. 
-- Marker molecule (MHC protein) 
\ 
~ Tho B ooll "'" ;, lho ontigoo 
and digests it, 
\ 
@j then displays antigen fragments bound to its own distinctive marker molecules. 
\ 
Lymphokines secretad by the T cell 
allow the 8 cell to multiply and mature 
into antibody-producing plasma cells. 
The combination of antigen 
fragment and marker molecule 
attracts the help 
of a mature, 
matching T cell. 
Released into the bloodstream, antibodies lock anta matching 
antigens. These antigen-antibody complexas are soon eliminated, 
either by the complement cascada or by the liver and the spleen. 
Source: Schindler, L. 1992. Undersranding rhe lmmune Sysrem. NIH pub. no. 90-3229. Bethesda, MD: U.S. Departmenl of Health and 
Human Services, )une 1992, p. 12. 
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lmmunoglobulins 
Antibodies are proteins whose function it is 
to bind the antigen, causing the antigen to 
lyse, precipitate out, or be more easily pha-
gocytized. The antigen-antibody complex can 
activate the complement system, or prevent 
viruses from reacting with receptor sites on 
cells. When the chemical nature of these pro-
teins are referred to, they are called immu-
noglobulins. The five main classes of immu-
noglobulins are IgG, IgM, IgA, IgD, and IgE. 
Immunoglobulins are composed of four 
polypeptide chains. Two of the chains are 
called the heavy chains and two are called the 
light chains. This unit of four is also called a 
monomer. Greek letters have been assigned to 
the various chains. The light chains are either 
kappa (K) or lambda (A) no matter what the 
class of the immunoglobulin. The heavy 
chains take their name from the immu-
noglobulin class. The heavy chains for IgG, for 
instance, are called gamma ("y), for IgA, alpha 
(a), for IgM, mu (¡..¡.). Immunoglobulins are 
bifunctional proteins in that one end of the 
molecule structure comprises a highly vari-
able region, that is, the amino acid sequence 
differs greatly from one antibody to another. 
This is the region which binds to or is comple-
mentary to the antigen. The other end of the 
molecule can bind to membrane receptors and 
is known as the constant region, or Fe frag-
ment. Macrophages, killer cells, mast cells, 
and placenta! cells all have Fe receptors that 
can bind to immunoglobulins. The fragment 
that binds to the antigen is composed of one 
end of the heavy chain and the light chain. 
The Fe fragment consists of the other end of 
the heavy chain. Since each monomer of an 
immunoglobulin has two heavy and two light 
chains, an immunoglobulin can bind two anti-
genic sites. 
Of al! the immunoglobulin classes, IgG is 
present in the highest concentration in the 
plasma and is responsible for most specific 
antibody reactions in the adult. It is the princi-
pal antibody secreted in the secondary re-
sponse and is the antibody passed from the 
maternal blood to the fetus that is responsible 
for protection of the fetus and newborn. Two 
of the four subdasses of IgG are able to acti-
vate complement. Also, macrophages and 
neutrophils have receptors on their cell sur-
faces that can bind to IgG. 
The antibody IgM is formed first. It is the 
first class of immunoglobulins to be formed in 
the fetus and the first in primary infections. It 
is a large molecule, a pentamer, composed of 
five monomer units, that is very efficient in 
agglutinating particles such as viruses. Pre-
sent in mucosa! secretions, breast milk, and 
saliva, IgA helps prevent antigens from gain-
ing access to the systemic circulation. It is the 
second most abundant immunoglobulin in the 
serum (10% to 15%). A fourth immunoglo-
bulin, IgE, is present in allergic reactions such 
as asthma and hay fever and in parasitic infec-
tions, and is also known as reaginic antibody. 
It is present in minute amounts in the plasma, 
but in the tissues is bound to the surface of 
mast cells. Not much is known about IgD. It is 
present in small amounts in the circulation 
and is involved in the regulation of immu-
noglobulin synthesis. 
Primary and Secondary Responses 
The responses of the immune system are dif-
ferent the first time an antigen is encountered 
from those of second or subsequent times. The 
first or primary response takes a longer time 
to develop and is not as specific nor as sus-
tained as the responses to secondary encoun-
ters. Whereas in a primary response IgM is 
formed first and IgG later, in the secondary 
response IgG titers are much higher than 
those generated in the primary response, and 
they are sustained for a longer period of time 
(Figure 2.7). That is why vaccinations to a 
particular microorganism are given severa! 
times, to generate clones of lymphocytes that 
can respond more quickly to the presence of 
an antigen. 
Complement 
The complement system is a series of about 20 
plasma proteins that acts as a bridge between 
the specific antibody response and the non-
Figure 2.7 Primary and secondary immune 
responses. Secondary immune responses are 
distinguished from primary ones by the 
decrease in the latent period, greater specific 
and more sustained response. 
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Source: Reprinted with permission from: Gallucci, B. 1987. The 
immune system and cancer. Oncology Nursing Forum 14(6 Suppll : 
3-12. 
specific inflammatory response. Complement 
acts to magnify and expand the specific anti-
body response. The complement proteins cir-
culate as proenzymes or inactive enzymes. 
When the complement cascade is triggered, 
often by an antibody-antigen complex, the 
proteins become active in a series of enzyma-
tic reactions that resemble the blood clotting 
cascade. The end product of both the classical 
and the alternative complement pathways is 
the membrane attack complex. This complex 
inserts a doughnut-shaped channel into the 
membrane, which allows lysis of the cell on 
which the antibody-antigen complex was 
attached. 
When the inactive complement proteins 
are activated, small polypeptides are released. 
These small "split products" are nonspecific 
activators of inflammation and act as chemo-
tactic agents, attracting white blood cells to 
the area; opsonins, enhancing phagocytosis of 
the antigen; and anaphylactoid agents, induc-
ing the release of histamine, and increasing 
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capillary permeability, which causes edema. 
These functions are vital to the clearance of 
microorganisms from the host. Individuals 
who have a congenital deficiency of one of the 
complement proteins are at higher-than-
normal risk of chronic infections or autoim-
mune diseases. 
T-Cell Responses 
The T cell is responsible for cell-mediated 
immunity, i.e., immunity carried out by cells. 
This type of immunity protects the body 
against intracellular organisms such as vi-
ruses and parasites, and malignant cells. T 
cells are also responsible for immunoregula-
tion through secretion of lymphokines. These 
responses can be broadly divided into two 
types, the cytotoxic response and the T-
helper response. 
T-Helper Cell Responses 
The T-helper (CD4) cell is the primary cell 
responsible for initiation of a specific immune 
response. Moving a T cell from its resting 
phase requires the binding of the T-cell re-
ceptor with a processed antigen, which is in 
turn bound to a MHC complex; it also re-
quires the presence of various cytokines such 
as IL-1. Interleukin- 1 produced by accessory 
cells such as macrophages, causes, along with 
antigen-MHC stimulation, a change in the 
plasma membrane and then an activation of 
IL-2 and the IL-2 receptor genes. This pro-
duction and secretion of IL-2 and its binding 
to the IL- 2 é:ell-membrane receptor drives the 
T cell through to the S phase of the cell cycle. 
The end result is a differentiated T cell that 
can produce lymphokines which mediate 
T-cell immunity, and activate cytotoxic T 
cells, whose function is to directly lyse cells. 
The T-helper cell is a majar producer of 
lymphokines. 
The T-helper response generates a de-
layed hypersensitivity reaction, the prototype 
of which is the positive PPD reaction. The 
results of the PPD test are read after 36 to 72 
hours, a delayed response that contrasts with 
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Figure 2.8 Activation of T cells. After a macrophage internalizes and processes antigen, it presents 
antigen fragments on its surface in conjunction with class 11 proteins to the helper T cell. Cytokines 
secreted by the macrophage help the T cell to mature. The activated T cell then secretes additional 
lymphokines that attract other immune cells to the area, activate cytotoxic T cells, and cause the 
growth of more T helper cells. 
~- Helper T cell receptor 
u T cells are rnobilizad 
Marker 
rnolecule 
(MHC protein) 
when they encounter a cell such 
as a rnacrophage ora B cell 
that has digestad an antigen 
~ and is displaying antigen fragrnents 
bound to its rnarker rnolecules. 
g O 
0 
'5 Lyrnphokines help !he g o 0 T cell to rnature. 
~ 
Mature u The rnature T cell, 
T cell -- alertad and activatad, 
secretes lyrnphokines. o 
/""' 00 00 ~ 000 ooo~u Sorne 
. 
lyrnphokines 
spur the 
;----Infectad cells growth of 
rnoreTcells. 
Sorne lyrnphokines 
anract irnrnune cells-
fresh rnacrophages, 
granulocytes, and 
u u ~~-·,-~ other lyrnphocytes-to !he s~e of infection. Yet other lyrn phokines direct the recruits once 
they arrive on the scene. 
killer cells and !rack down 
body cells infectad by 
viruses. 
Source: Schindler, L. 1992. Undersranding rhe lmmune Sysrem. NIH pub. no. 90-3229. Bethesda, MD: U.S. Department o( Health and 
Human Services, )une 1992, p. 13.) 
the B-cell or immediate hypersensitivity re-
sponse. A typical immediate hypersensitivity 
response is a penicillin reaction. The T-cell 
responses control intracellular pathogens such 
as Mycobacteria, fungi, and viruses, and elimi-
nate altered and malignant cells. Graft rejec-
tion and graft-versus-host disease are also 
T -cell responses. 
Cytotoxic T -Cell Responses 
The cytotoxic T-cell response requires direct 
physical contact between the cytotoxic T cell 
(CD8 lymphocyte) and the target cell (Figure 
2.8). Generally, the CD8 cells are MHC class I 
restricted, meaning that the target cells must 
have MHC class 1 antigens expressed on their 
surfaces. Since almost every cell in the body 
expresses MHC class 1 antigens, almost every 
cell can be killed by cytotoxic T cells. 
Before directed cell k.illing begins, specific 
T-helper cells are stimulated by the antigen. 
This expanded pool of T-helper cells then pro-
duces IL-2. It is in response to both this IL-2 
and the antigen presented with the MHC class 
I molecule that the resting cytotoxic T cell is 
stimulated to proliferate and differentiate. The 
killing of the target cell is the result of a series 
of steps, starting with the joining or conjuga-
tion of the cytotoxic T cell and the target ce!!. 
Conjugation is dependent on the binding of 
the T-cell receptor-CD3 complex with the 
antigen-MHC class I complex on the target 
ce!!. A series of membrane changes occur in 
the cytotoxic T cell generating a signa! in the 
protoplasm. Orientation of the Golgi com-
plexes and granules in the cytotoxic T cell 
toward the target cell occurs next, then the 
contents of the granules are released in the 
space between the cytotoxic T cell and the 
target ce!!. The cytotoxic T cell migrates away 
and is ready to start the cycle again; shortly 
after, the target celllyses. Any one cytotox.ic T 
cell can kili multiple target cells and yet not be 
harmed itself. The target cell is lysed when 
pores or channels form in the target cell mem-
brane in a manner reminiscent of complement 
lysis. However, the proteins required for each 
type of reaction are different molecules. 
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TUMOR IMMUNOLOGY 
The first experimental system used to study 
tumor biology was the transplantation of tu-
mors between animals. When this work was 
started in the late-1800s, inbred strains of ani-
mals were unknown, thus, what the scientists 
were really studying was allogeneic transplan-
tation and responses to antigens. Around the 
same time, Dr. Coley (see Chapter 1) observed 
tumor regression in a few patients who had 
serious infections. He devised a vaccine that 
would simulate a serious infection and tested 
it in 1200 patients; 270 of these had complete 
regression of tumor. Now we know that re-
sponses to infections, tumors, and transplanta-
tion are all related and that insights into the 
mechanisms of one are relevant to the other 
two. The other side of understanding immune 
responses to infections and transplantation is 
understanding tolerance to self molecules, an 
area of study that has helped in discovering 
the way tumors can evade recognition and de-
struction by the immune system. 
lmmune Surveillance 
and Tumor Antigens 
In the 1950s, knowledge of the body's reac-
tion to tumors was synthesized by Mac-
Farlane Burnett into a theory of a process 
termed immune surveillance. Expressed in 
somewhat popular terms, the theory states 
that (1) all individuals form tumor cells; (2) 
not everyone develops a malignancy; and (3) 
it is the immune system that prevents the 
development of tumors. As stated, the theory 
can not be directly tested because it is almost 
impossible to prove the negative, an absence 
of tumors. However, worded differently, this 
theory implies that tumors have antigens that 
under appropriate circumstances can be iden-
tified by the immune system. In animal 
models, the tumor antigens are called tumor 
transplantation antigens, reflecting the design 
of the experiments to test these ideas. One 
way to study tumor rejection and tumor-
associated transplantation antigens is to inject 
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nonviable tumor cells (obtained from another 
animal of the same inbred line) into an ani-
mal as a vaccine. When the animal is later 
challenged with live tumor cells, it is able to 
reject the tumor. ·A control animal without 
prior exposure to the tumor cell vaccine is 
unable to reject the live tumor cells and de-
velops a malignancy. 
Because transplantation experiments with 
live tumor cells are not feasible in humans, 
tumor antigens are termed tumor-associated 
antigens or oncofetal antigens. Very few an-
tigens in humans are associated exclusively 
with malignancy. Most antigens are also pre-
sent in other pathologic states or in the fetus. 
Two tumor-associated antigens that are use-
fui clinically are alpha fetoprotein (AFP) and 
carcinoembryonic antigen (CEA) . Carcino-
embryonic antigen is expressed in gastroin-
testinal and breast cancers, AFP in hepato-
cellular and testicular cancers. Alpha feto-
protein has been used in a few screening 
programs for the detection of hepatocellular 
tumors, but these two antigens are more fre-
quently used as indicators of disease progres-
sion. Following surgery for the cancers men-
tioned above, the plasma concentration of the 
oncofetal antigen usually drops dramatically. 
If disease recurs, the levels rise once again. A 
rise in CEA levels might be the first indicator 
of relapse. However, CEA levels rise in only 
60% to 94% of patients, so a negative CEA 
report does not guarantee an absence of 
metas tases. 
Although tumor antigens have been dis-
covered, not all experimentally induced tu-
mors produce antigens recognized by the im-
mune system and sorne evoke only a "weak" 
immune response. This is also true of tumors 
that arise spontaneously, in animals as well as 
in humans. On the surface of any tumor cell, 
however, there are many surface marker mol-
ecules, such as differentiation antigens, tissue-
specific antigens, and receptors, sorne of 
which may be exploited for identifying, classi-
fying, and treating the malignancy. Tumor-
infiltrating lymphocytes can recognize sorne 
tumor-associated antigens. 
In the clinic, tumor antigens are detected 
by monoclonal antibodies to these antigens. 
As noted above, these monoclonal antibodies 
can be used in screening and determining 
tumor progression. They can also be linked 
to special stains and used in the diagnosis of 
the tumor type and subtype. For instance, 
the CD10 antigen, also known as the com-
mon acute lymphoblastic leukemia antigen 
(CALLA), appears in the leukemic cells of ap-
proximately 70% of children diagnosed with 
acute lymphocytic leukemia. This antigen is 
also seen in Burkitt's and follicular lym-
phomas. Tumor antigens can also be used to 
determine the T- or B-celllineage and the dif-
ferentiation state of leukemias. Cells positive 
for CALLA are of the B-celllineage. Monoclo-
nal antibodies to surface antigens are used to 
determine the tissue of origin in undifferenti-
ated or poorly differentiated tumors. Mono-
clona) antibodies can help distinguish tumors 
of epithelial and connective tissue origins. In 
clinicaJ trials, monoclonal antibodies are now 
being linked with radioactive compounds, tra-
ditional chemotherapeutic agents, or toxins to 
determine their utility either in imaging oras 
therapy. (See Chapter 7.) 
Oncogenes, Tumor-Suppressor 
Genes, and Tumor Antigens 
Cancer is a disease of cell growth and division; 
underlying this abnormal cellular state are ge-
netic changes. The genetic changes that arise in 
carcinogenesis include point mutation (the 
change of one nucleotide base in the gene); gene 
amplification, alterations in the gene control 
mechanisms; chromosomal deletions and inser-
tions; and chromosomal abnormalities. As the 
tumor progresses, more and more genetic 
changes accumulate. One of the main functions 
of the gene is to code for proteins. Therefore, if 
carcinogenesis is initiated with a genetic change 
and that change results in an altered protein, 
then that protein could be recognized, allowing 
diagnosis, and become a target for chemo-
therapy or biological agents. 
The genes that have been associated with 
carcinogenesis are caBed oncogenes. On-
cogenes were first recognized in experimental 
virology, where it w~as observed that viral 
genes could transform cells in culture. When 
these genes were placed into cell cultures, 
they caused the phenotype of the cell to 
change and take on the appearance of a tumor 
cell. Since the cells were in a culture, the pro-
cess was called transformation rather than 
carcinogenesis. It was then discovered that 
viral oncogenes had a normal cell equivalent, 
called proto-oncogenes. lf these genes were 
first recognized for their normal function, per-
haps then they would be called growth, divi-
sion, and repair genes instead of oncogenes. 
These genes are responsible for controlling the 
highly regulated processes of the cell cycle, 
that is, the sequencing and coordination of the 
cell through the G(}l G11 S, G21 and mitosis 
phases. The initiating event in cell growth and 
division is termed a signa!. The signa!, which 
might be a growth factor, hormone, cytokine, 
or antigens, initiates a complex series of ac-
tions at the surface membrane and in the cyto-
plasm and nucleus. Proto-oncogenes are in-
volved in coding for the proteins that act as 
growth factors, growth factor receptors, and 
signaling complexes at the membrane; second 
messengers in the cytoplasm; and regulators 
of gene expression. 
The existence of tumor-suppressor genes 
or recessive oncogenes was first hypothesized 
from epidemiologic data. Knudson developed 
a mathematical model to explain the differ-
ence in age of onset of unilateral and bilateral 
retinoblastoma. He suggested that individuals 
with familia! disease with increased risk for 
bilateral disease were born with one defective 
gene of the pair of maternal and paternal 
genes that control retinoblastoma. (Most 
genes in the body, except those on the X and Y 
chromosomes in males, occur as pairs.) The 
mutation of one allele of the pair of genes 
occurs earlier in life in patients with familia! 
disease than in those with unilateral disease. 
Unilateral disease occurs Jater in life than bi-
lateral disease and requires that mutations oc-
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cur in both the maternal and paternal genes; 
since the presence of at least one functioning 
gene inhibits the growth of the tumor. Great 
progress has been made in identifying the 
tumor-suppressor genes in retinoblastoma, 
Wilms' tumor, von Recklinghausen' s neuro-
fibromatosis, familia! adenomatous polyposis, 
and colorectal carcinomas. These genes have a 
variety of actions, including suppression of 
cellular transcription factors, DNA replica-
tion, and gene transcription. 
Clearly, regulation of normal growth and 
division is complex and under tight control. 
This complexity in itself may Jead to multiple 
metabolic errors. There are, however, normal 
cellular mechanisms that limit or correct for 
these errors. Oncogene products, growth fac-
tors, and growth factor receptors are alllinked 
in this complex regulatory system. In malig-
nant diseases, sorne of the oncogenes are 
structurally different from their proto-onco-
gene counterparts. Other oncogenes are ex-
pressed in higher amounts in cancer cells than 
in normal cells, and tumor-suppressor genes 
may be entirely lack.ing in the tumor cells. In 
the future, the protein products of oncogenes 
might be targets of immunotherapies such as 
antibodies directed to growth factor receptor 
produced by an oncogene; the manufacture of 
suppressor gene products may lead to the de-
velopment of new biological agents. (See 
Chapter 16.) 
lmmune Responses to Tumors 
There is sorne evidence that almost every im-
mune response that has been identified, in-
cluding cellular and antibody-mediated im-
munity, is also generated as a response to 
tumor cells. Probably the most protective re-
sponses to tumors are cellular responses, 
which are similar to those generated against 
viruses. The important cells in these reactions 
are cytotoxic T cells, macrophages, NK cells, 
and antibody-dependent cytotoxic cells. Since 
the biology of the tumor changes with tumor 
progression, it may be that the relative impor-
tance of one type of immune response differs 
at the various tumor stages. 
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Sorne lines of evidence for an immune 
response to tumors come from the study of 
histopathology. To establish a diagnosis of 
cancer in humans, biopsied tissue is sent to 
the pathology lab9ratory, where it is stained 
and examined. Sorne tumors have marked 
infiltrates, often called a mononudear infil-
trate (lymphocytes and macrophages), which 
suggests that the tumor has stimulated an 
immune response in the individual. In sorne 
instances (medullary carcinoma of the breast, 
for example) the presence of a mononuclear 
infiltrate means a more favorable prognosis 
for the patient. Other clinical signs that have 
suggested an immune response to tumors is 
the waxing and waning of tumors. In such 
cancers as melanomas, the lesions are visible. 
Sorne of the lesions will disappear from one 
area and other tumor deposits will appear 
simultaneously at distant sites. lt has been 
suggested that the reason for tumor fluctua-
tions is that the immune responses were able 
to eliminate the tumor from one small area 
but not to control the progression of the dis-
ease in other areas. Spontaneous regression of 
a diagnosed malignancy is an extremely rare 
event, but there have been reports of regres-
sion in carcinoma of the kidney, neuro-
blastoma, choriocarcinoma, and melanoma. 
Again, immune mechanisms appeared to offer 
the best explanation for the regression. Al-
though clinica1 evidence suggests the exis-
tence of immune responses to tumors, it does 
not constitute definitive proof. Animal experi-
ments provide further evidence for immune 
responsiveness to tumors; the development of 
a cancer-preventing vaccine would be a 
definitive proof of the theory of immune 
surveillance. 
Ceii-Mediated Cytotoxicity 
Cytotoxic T cells can recognize and destroy 
malignant cells by the same mechanisms they 
use to recognize and destroy cells infected 
with viruses. The cytotoxic T-cell receptor at-
taches to the tumor antigen, which is com-
plexed with the class I MHC antigens. The 
direct contact and binding results in the re-
lease of enzymes and lysis of the tumor cell 
within a few minutes. As with many other 
specific cytotoxic T-cell reactions, T-helper cell 
activation is necessary. The T-helper cells are 
al so activated by the presentation of the tumor 
antigens linked to MHC on macrophages, and 
activation of T-helper cells can also result in 
nonspecific cytotoxicity. These cells release 
lymphokines, which activate macrophages in 
the area of the tumor. The activated macro-
phages release lytic enzymes, proteases, and 
reactive oxygen intermediates which destroy 
the tumor cells. ln another type of cytotox-
icity, antibody-dependent cytotoxicity, anti-
bodies bound to a cytotoxic cell, either an NK 
cell or a macrophage, cross-link the cytotoxic 
and tumor cells. This binding creates changes 
in the cell membrane of the macrophage, caus-
ing release of lytic granules and death of the 
tumor cell. Natural killer cells are also re-
sponsible for the killing of tumor cells but, 
unlike the cytotoxic T cells, NK cells do not 
need prior exposure to generate a cytotoxic 
response to the tumor cell. 
Antitumor Antibodies 
In animal experiments, the injection of tumor 
cells has resulted in the production of anti-
tumor antibodies. The binding of these anti-
bodies to macrophages can lead to tumor cell 
lysis as described above in antibody-depen-
dent cytotoxicity. Antitumor antibodies could 
also act as an opsonin. The binding of anti-
bodies to the surface of tumor cells allows 
phagocytosis by macrophages to occur more 
readily. Binding of antibodies may also result 
in the activation of the complement system 
and the destruction of the tumor ce!!. Paradox-
ically, in sorne animal models it has been 
shown that the production of antibodies to 
tumors interfered with cell-mediated anti-
tumor immune responses. Many of the studies 
in humans of antitumor antibodies have been 
conducted in patients with melanoma. Very 
few of these patients, about 6%, generate anti-
tumor antibodies. 
Cytokines 
Cytokines are low-molecular-weight regula-
tory proteins produced by various cells. If 
these proteins are propuced by lymphocytes, 
they are called lymphokines; if by monocytes, 
they are referred to as monokines. Several 
cytokines are k.nown to have an antitumor 
effect; they may act alone or in concert with 
other cytokines. Interferons, tumor necrosis 
factors, and interleukin-2 are sorne of the 
more well-k.nown cytokines with cytotoxic or 
antiproliferative effects. For instance, inter-
feron gamma activates NK cells, thereby in-
creasing NK cytotoxicity. The interferons are 
antiproliferative agents and can increase the 
expression of MHC antigens, which are neces-
sary for T-cell activation. Tumor necrosis fac-
tors are secreted by macrophages, NK cells, 
and T-helper cells. They can directly lyse 
tumor cells and act in a synergistic fashion 
with interferon. The cloning of the genes for 
cytokines and their commercial production 
has led to an explosion of knowledge about 
these powerful cell regulators and to their ex-
ploitation for therapeutic purposes. 
Tumor Escape Mechanisms 
Obviously, when a patient is diagnosed with 
a malignancy, whatever antitumor immune 
mechanisms were present were not effective. 
Severa! different mechanisms are k.nown by 
which tumors apparently evade the immune 
system. Antigenic modulation, one of the es-
cape mechanisms, is readily observed in ani-
mal models. For instance, an animal that is 
immunized to a tumor may produce anti-
bodies to the tumor antigen. The antibodies 
form complexes with the tumor antigen and 
are taken into the cell by endocytosis or shed to 
the environment. As long as the antibodies are 
present, the antigen is lost from the tumor sur-
face and cannot be recognized by a cytotoxic T 
cell-killing is prevented. Alternatively, shed-
ding of tumor antigens or tumor antigen-
antibody complexes may block the activity of 
the cytotoxic cells. 
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In humans, as the tumor progresses, it 
may be that the tumor cells that are most 
easily recognized by the immune system are 
killed. Those tumor cells that are left may not 
express the tumor cell antigen and are able to 
proliferate without stimulating an immune 
response. Tumor ce lis may be able to " sneak 
through" the immune surveillance network. 
According to this theory, so few cells and 
tumor antigens are present early in the 
growth of a tumor, that the immune system 
is not stimulated. Later in the natural history 
of the tumor, there is a sufficient amount 
of tumor antigen present to stimulate the 
immune system, but by then the tumor is too 
large to be controlled by the immune re-
sponse. 
Cell-adhesion molecules are expressed on 
most somatic cells in the body. These mole-
cules are necessary for the adherence of cyto-
toxic cells to a target cell befare lysis can 
ensue. During the natural history of tumors, 
there are multiple genetic changes that are 
reflected in the phenotype of the cell. One of 
the changes that occurs in tumor cells is the 
loss of these cell-adhesion molecules. With 
the loss of these molecules, cytotoxic cells 
cannot bind as tightly to the malignant cells 
and thus the tumor can escape immune 
surveillance. 
Class 1 MHC molecules on the target cell 
and the presence of antigen are necessary for 
cytotoxic T-cell killing. Transformation of 
cells to a malignant phenotype occurs along 
with the loss or a decrease in the expression 
of class 1 MHC molecules. Theoretically, the 
loss of these molecules may allow the tumor 
cell to escape recognition by the cytotoxic 
cell. 
Besides these mechanisms, tumor cells 
may produce factors that inhibit immune re-
sponsiveness. For instance, tumor cells may 
secrete prostaglandins, which inhibit inflam-
mation and block synthesis of chemotactic 
factors. This would limit the number of lym-
phocytes and monocytes in the area of the 
tumor. 
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AUTOIMMUNE DISEASES 
Autoimmune diseases are another group of 
diseases in which biological therapies hold 
great promise. When the immune system re-
acts against self antigens, the ensuing state is 
called autoimmurtity. Approximately 6% of 
the population suffer a chronic debilitating 
autoimmune disease. Autoimmune diseases 
are classified as (1) organ-specific diseases 
such as Addison's disease, Graves' disease, 
myasthenia gravis, and poststreptococcal 
glomerulonephritis or (2) systemic diseases 
such as ankylosing spondylitis, multiple scle-
rosis, rheumatoid arthritis, and systemic 
lupus erythematosus. The current therapies 
for autoimmune diseases are mainly those of 
nonspecific immunosuppression, including 
pharmacological agents such as steroids and 
cyclosporine, plasmapheresis, lymph node ir-
radiation, and thymectomy. lt has been sug-
gested that more specific biological therapies 
will become available for these diseases in the 
future that will have fewer side effects than 
present therapies and will be directed at the 
immunological abnormalities. 
Autoimmunity is the loss of self tolerance. 
Normally, lymphocytes that recognize self an-
tigens are eliminated, usually in the fetus, in a 
process called clona! deletion. Most adults 
have clona} anergy, that is, lymphocytes that 
can react against self molecules are present in 
the circulation but do not react. This state of 
self tolerance must be maintained through 
regulation of immune responses. As discussed 
earlier, T-helper cells, T-suppressor cells, the 
interactions of the MHC antigens and T-cell 
receptors, and the cytokines are all responsi-
ble for regulatory reactions. 
All these reactions are currently being 
studied to determine their role in autoimmune 
diseases. A great deal of research is now being 
done to determine the roles of MHC antigens 
and T-cell receptors in autoimmune diseases. 
1t appears that many autoimmune diseases 
are associated with MHC class 11 genes and 
may result from the inappropriate expression 
of MHC antigens on cells in the target tissue. 
The relative risk of developing an autoim-
mune disease is high for individuals who pos-
sess certain MHC alleles. Individuals with the 
HLA-827 allele, for instance, have a 90% risk 
of developing ankylosing spondylitis, and 
those with the HLA-DR3/ DQW8 allele have a 
100% risk of developing insulin-dependent di-
abetes. The exact mechanisms of the patho-
genesis of these diseases are being explored in 
animal models, along with specific therapies 
directed at the T-helper cell receptors and spe-
cific T-cell clones. Autoimmune reactions may 
involve the B-cell system with the production 
of autoantibodies, the T-cell system with the 
inappropriate activation of cytotoxic T cells or 
T-helper cells, or both T-cell and B-cell im-
mune responses. 
Current experimental approaches to auto-
immune diseases in animal models include 
the administration of monoclonal antibodies 
(Kuby, 1992; Wolsy, 1988). In mice with an 
autoimmune lupus-like syndrome, treatment 
with monoclonal antibodies to the CD4 mole-
cule (T-helper cell) and to the IL- 2 receptor 
has led to recovery and relief of symptoms. 
The administration of anti-CD4 antibodies 
prevented the lymphocytic infiltration of the 
pancreas and the relief of diabetic symptoms 
in another experimental animal model (Wald-
mann, 1988). Monoclonal antibodies to MHC 
molecules prevented the development of ex-
perimentally induced multiple sclerosis. 
Many strategies other than monoclonal anti-
body therapies are also being studied for their 
ability to modify the inflammatory and im-
mune responses responsible for autoimmune 
diseases, rejections of transplants, and hyper-
sensitivity states. 
SUMMARY 
The immune system serves as the body's de-
fense system through the functions of protec-
tion from pathogenic organisms, surveillance, 
and homeostasis. Immune responses are di-
vided into two types-innate and adaptive 
immunity. lnnate or nonspecific defenses in-
volve such mechanisms as intact skin and mu-
cous membranes, the acidic environment of 
the stomach, the cleansing effect of tears, sa-
liva, exfoliation of the skin, and the inflamma-
tory response. These defenses form the body's 
first line of defense ag,ainst pathogens. White 
blood cells, neutrophils, basophils, and eo-
sinophils are important primarily in non-
specific defenses. 
If innate immunity fails, adaptive immu-
nity is enlisted. Specific immune responses 
recognize foreign antigens while tolerating self 
molecules. The hallmarks of adaptive immu-
nity are memory and specificity. A additional 
property of specific immune responses is their 
ability to react in a more specific and sustained 
fashion upon the second and subsequent en-
counters with the antigen. Lymphocytes and 
macrophages are primarily involved in spe-
cific immune reactions. Lymphocytes can be 
classified as B cells responsible for the pro-
duction of antibodies (immunoglobulins); T 
cells are important in cytotoxic and regulatory 
reactions. 
The immunoglobulin receptor on the B 
cell and the T-cell receptor are responsible for 
the specific recognition of the antigen. The 
major histocompatibility genes control inter-
actions among cells of the immune system. 
These genes code for molecules (MHC anti-
gens) on cell surfaces that are recognized by 
T lymphocytes which require the antigen to 
be complexed to self MHC antigens for rec-
ognition. Cytokines are powerful mediators 
released during inflammatory and immune 
reactions. Although separate, there is signifi-
cant interaction between innate and adaptive 
immunity and both are typically required to 
effect a sufficient response to eliminate 
pathogens. 
The theory of immune surveillance im-
plies that the immune system is capable of 
recognizing and destroying tumors. When a 
tumor is diagnosed in a patient, theoretically 
that tumor has evaded or sneaked through the 
immune surveillance system. Under appropri-
ate conditions the immune system can recog-
nize tumor associated antigens. T -cell re-
sponses to tumor cells resembles immune 
responses to viruses. B-cell responses to tu-
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mors also occur. Both activated macrophages 
and natural killer cells can lyse tumor cells, 
natural killer cells without prior exposure. 
Rapid advances in technology such as ge-
netic engineering and recombinant DNA tech-
nology, coupled with a more complete under-
standing of the immune response and the 
molecular basis of oncogenesis have led to the 
utilization of biological proteins in the treat-
ment of cancer. Numerous cytokines; inter-
ferons, interleukins, hematopoietic growth 
factors, tumor necrosis factor and monoclonal 
antibodies, are now in clinical investigation or 
have received regulatory approval. As re-
search continues to progress, new avenues of 
treatment will become available. 
Oncogenes when functioning normally 
regulate cellular growth, division and differ-
entiation. Suppressor genes or recessive on-
cogenes inhibit the development of the malig-
nant phenotype in a cell. In the future, protein 
products of oncogenes or suppressor gene 
products may be used as biological therapy. 
Autoimmune states (glomerulonephritis, 
systemic lupus, arthritis) are currently being 
investigated as to the underlying immu-
nologic abnormalities. In the future, biolog-
icals may also be manufactured that will con-
trol these illnesses. 
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